Accurately Identifying Opportunities for a New Treatment in Haematology: Synergy Highly Commended for Best Business Impact at 2021 BOBI Awards

We are pleased to announce that recent research conducted by Synergy team members Jon, Lucy & Larissa in partnership with Sanofi’s Simon Barnes has been shortlisted as a Highly Commended entry in the Best Business Impact category for the 2021 BOBI Awards.

The entry, ‘Accurately Identifying Opportunities for a New Treatment in Haematology’, describes how our research insights helped optimise commercial decision making and ensured resources were invested where patient needs are greatest.

Cold agglutinin disease is a rare disease with conflicting published data regarding its incidence and prevalence – and therefore the opportunity for a new treatment option from Sanofi was unclear.

By designing research to robustly project numbers of patients seen by haematologists eligible for the new treatment, our research was able to empower Sanofi to make accurate decisions regarding investment in this area and thus enhance the quality of the company’s business decision making

We look forward to the Awards Ceremony at the BHBIA Conference on the 10th of May, and wish the best of luck to the other finalists!

More To Explore

Blog

Congratulations to Freya and Larissa!

We are very pleased to announce the promotion of Freya to Research Executive, after settling in so quickly to become a valued Synergy team member.